BiomX (PHGE) Amortization of Deferred Charges (2022 - 2023)
BiomX (PHGE) posted Amortization of Deferred Charges of $114000.0 for Q4 2023, down 6.56% sequentially from $122000.0 in Q3 2023, and up 34.12% YoY from $85000.0 in Q4 2022.
BiomX (PHGE) Amortization of Deferred Charges (2022 - 2023) Analysis & Trends
BiomX has reported Amortization of Deferred Charges for 2 years, with the latest figure at $114000.0 in Q4 2023.
- Quarterly Amortization of Deferred Charges rose 34.12% year-over-year to $114000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $567000.0 (up 22.46% YoY) and the FY2023 annual result came in at $567000.0, up 22.46% from the prior year.
- Amortization of Deferred Charges fell to $114000.0 in Q4 2023 per PHGE's latest filing, from $122000.0 in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $263000.0 in Q2 2023 and troughed at $68000.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | BiomX | 351,774.34 | -816,225.66 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 114,000.00 |
| Dec 31, 2023 | 114,000.00 |
| Sep 30, 2023 | 122,000.00 |
| Sep 30, 2023 | 122,000.00 |
| Jun 30, 2023 | 263,000.00 |
| Jun 30, 2023 | 263,000.00 |
| Mar 31, 2023 | 68,000.00 |
| Mar 31, 2023 | 68,000.00 |
| Dec 31, 2022 | 85,000.00 |
| Dec 31, 2022 | 85,000.00 |
| Sep 30, 2022 | 127,000.00 |
| Sep 30, 2022 | 127,000.00 |
| Jun 30, 2022 | 126,000.00 |
| Jun 30, 2022 | 126,000.00 |
| Mar 31, 2022 | 125,000.00 |
| Mar 31, 2022 | 125,000.00 |